ARDX
Ardelyx, Inc.
Healthcare — Biotechnology
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Price History
Fundamentals
| Market Cap | $1.26B |
| P/E Ratio (TTM) | - |
| Forward P/E | 9.90 |
| EPS (TTM) | $-0.24 |
| Dividend Yield | - |
| Profit Margin | -13.58% |
| Revenue Growth | 27.50% |
| ROE | -39.46% |
| Debt/Equity | 157.53 |
| Recommendation | Strong Buy 1.1 |
| Analyst Target | $16.30 |
| Analysts | 10 |
| Next Earnings | Aug 6, 2026 AMC |
| Indexes | - |
Technical Indicators
| RSI (14) | 39.1 |
| Beta | 0.58 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $8.40 |
| 52-Week Low | $3.80 |
| 50-Day Avg | $6.11 |
| 200-Day Avg | $6.10 |
| Avg Volume | $4.03M |
| Volume | $2.15M |
Performance Analysis
BULLISHARDX shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jun 30, 2026 21:07 UTC
Back to Screener Export Report